Literature DB >> 2121738

In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.

G Chen1, W J Zeller.   

Abstract

Resistance of a rat ovarian tumor cell line (O-342/DDP) to cisplatin was induced in vitro by stepwise increase of cisplatin concentrations. Both chemosensitive parental cells (O-342) and resistant O-342/DDP cells grow in a monolayer and enter log-phase growth about 24 h after seeding (cell population doubling time in log-phase growth is about 24 h). O-342/DDP cells show a 33-fold resistance to cisplatin as compared to O-342 cells (ID50 = 33 microM in O-342/DDP vs 1 microM in O-342 cells). The intracellular total glutathione (GSH + GSSG) of O-342/DDP cells was twice as high as that of O-342 cells (3.04 vs 1.37 nmol/10(6) cells), while the intracellular GSSG was increased by 26% in O-342/DDP cells compared to O-342 cells. DNA interstrand crosslinks were found to be 8.5 times higher in O-342 cells than in O-342/DDP cells (204 vs 24 rad equiv.), following cisplatin treatment. DNA single-strand breaks were approximately doubled in the sensitive line as compared to the resistant line following exposure to cisplatin. Chromosome analysis uncovered a change in the karyotype of O-342/DDP cell as compared to O-342 cells. In the sensitive line hyperploid (3n) clones, in the resistant line near-diploid clones predominated. Both DL-buthionine-(S,R)-sulfoximine and 3-aminobenzamide were able to sensitize the resistant line towards cisplatin. Thus, the present results suggest that mechanisms for cisplatin resistance in this tumor line apparently are multi-factorial, and include a higher intracellular GSH content and an increased repair activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121738     DOI: 10.1007/bf01612991

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  17 in total

1.  Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia.

Authors:  A Mansouri; K J Henle; A M Benson; A J Moss; W A Nagle
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

2.  Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.

Authors:  O W Griffith
Journal:  Anal Biochem       Date:  1980-07-15       Impact factor: 3.365

3.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

4.  Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).

Authors:  B A Teicher; S A Holden; M J Kelley; T C Shea; C A Cucchi; A Rosowsky; W D Henner; E Frei
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

5.  Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion.

Authors:  P A Andrews; M P Murphy; S B Howell
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

6.  Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II).

Authors:  P Bedford; M C Walker; H L Sharma; A Perera; C A McAuliffe; J R Masters; B T Hill
Journal:  Chem Biol Interact       Date:  1987-01       Impact factor: 5.192

7.  Quenching of DNA:platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells.

Authors:  K Micetich; L A Zwelling; K W Kohn
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

8.  Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells.

Authors:  R A Hromas; P A Andrews; M P Murphy; C P Burns
Journal:  Cancer Lett       Date:  1987-01       Impact factor: 8.679

9.  Determination of intracellular reduced glutathione and glutathione related enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines.

Authors:  G Chen; E Frei; W J Zeller
Journal:  Cancer Lett       Date:  1989-08       Impact factor: 8.679

10.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.

Authors:  V M Richon; N Schulte; A Eastman
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

View more
  8 in total

1.  Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line.

Authors:  G Chen; K J Hutter; J Bullerdiek; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Cell cycle effects of thaliblastine.

Authors:  F Seifert; D K Todorov; K J Hutter; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Revisiting the BRCA-pathway through the lens of replication gap suppression: "Gaps determine therapy response in BRCA mutant cancer".

Authors:  Sharon B Cantor
Journal:  DNA Repair (Amst)       Date:  2021-08-13

4.  Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo.

Authors:  G Chen; W J Zeller
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells.

Authors:  G Chen; K J Hutter; W J Zeller
Journal:  Cell Biol Toxicol       Date:  1995-10       Impact factor: 6.691

Review 6.  Anticancer Alkaloids from Trees: Development into Drugs.

Authors:  Tasiu Isah
Journal:  Pharmacogn Rev       Date:  2016 Jul-Dec

7.  Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.

Authors:  Y Kikuchi; J Hirata; K Yamamoto; K Ishii; T Kita; K Kudoh; T Tode; I Nagata; K Taniguchi; M Kuwano
Journal:  Jpn J Cancer Res       Date:  1997-02

Review 8.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.